The Compliance Enforcement Ladder: Five Escalation Levels from Warning Letter to ARTG Cancellation

Updated: 2026-11-11 · GRZAN Regulatory Team · Verification date 2026-10-20

1. Key takeaways

The TGA’s compliance response is an escalating ladder: warning letter → enforceable directions notice → infringement notice → suspension → cancellation, running in parallel with civil and criminal liability. Civil penalties reach a maximum of 5,000 penalty units for an individual and 50,000 penalty units for a body corporate; criminal penalties reach a maximum of 5 years imprisonment or 4,000 penalty units. The ladder matters because each rung carries its own response logic: an early-stage letter calls for prompt rectification with evidence retained, while a suspension or cancellation calls for argument and evidence directed at the specific statutory grounds invoked. This article maps each rung to its clause basis so that the response can be aimed precisely. A warning letter answered thoroughly and on time is, in most cases, the cheapest point in the whole ladder at which to resolve a problem; delay at that first rung is what pushes a matter onto the later, more expensive rungs.

2. Legal basis

Each rung of the ladder has its own statutory foundation, and the penalties that run alongside it are capped at fixed amounts in penalty units. The sources below set out those foundations and caps. Because the monetary amounts are expressed in penalty units, which are calculated under the Crimes Act 1914, the dollar value of any cap must be worked out at the rate current when the exposure is assessed. The guidance page cited in item 1 is also where the TGA publicises compliance outcomes, making it useful for monitoring enforcement activity.

  1. Warning letters: TGA, Compliance actions and outcomes (3 July 2026) — listing the non-compliance found, the rectification required, and the follow-up action where rectification does not occur within the specified period.
  2. Enforceable directions notices: issued by the Minister for Health, and may require relabelling, destruction and similar steps; non-compliance can lead to court proceedings.
  3. Infringement notices: section 42YKA of the Therapeutic Goods Act 1989 (amount formula; penalty units calculated under the Crimes Act 1914).
  4. Civil penalties: a maximum of 5,000 penalty units for a natural person and 50,000 penalty units for a body corporate.
  5. Criminal penalties: a maximum of 5 years imprisonment and a maximum of 4,000 penalty units (therapeutic goods).
  6. Suspension: section 41GA(1)(b) — suspension is possible where circumstances may exist that would constitute grounds for cancellation.
  7. Cancellation: sections 41GK, 41GL, 41GM and 41GN (for example: sponsor-initiated cancellation under section 41GL(d); non-payment of annual charges under section 41GL(f)).
  8. Enforceable undertaking: where an undertaking is breached, the Minister for Health may apply to the Federal Court for orders.
  9. [Practical estimate] The existence and variability of additional conditions of inclusion are confirmed in TGA guidance, but no specific clause number is given on the page.

3. Expert insights

Insight 1: suspension and cancellation rest on different clauses and offer different remedies. Suspension operates under section 41GA(1)(b), on the basis that grounds for cancellation may exist, and is therefore a preventive measure; cancellation operates under sections 41GK–41GN, each with its own independent triggering circumstances. Responding to a suspension means demonstrating that no grounds for cancellation exist, while responding to a cancellation means producing evidence targeted at the specific clause invoked. Reading the two regimes side by side before responding prevents a sponsor from answering a preventive measure with arguments that only fit a completed cancellation. The response should engage with the provision the regulator relied on, clause by clause.

Insight 2: the corporate cap for civil penalties is ten times the individual cap. Individuals face up to 5,000 penalty units and bodies corporate up to 50,000. This order-of-magnitude difference means the corporate entity is usually the primary target of enforcement, and shielding of individual liability cannot substitute for compliance at the entity level. In risk terms, the corporate multiplier is the figure that should drive any quantified exposure assessment, and individual liability is best treated as a governance matter in its own right rather than as an alternative to entity-level remediation.

Insight 3: the enforceable undertaking is a negotiation channel. It sits outside the response ladder and is a mechanism by which the company proactively offers remediation commitments. If the undertaking is breached, the Minister may apply to the Federal Court for orders, so the content of the commitment must match what the company can actually execute, and every commitment should be traceable to a resourced, verifiable remediation action. Because the undertaking replaces a coercive outcome with a negotiated one, it is typically worth exploring early — but only when the underlying non-compliance is genuinely capable of being fixed.

4. Practical recommendations

  • Open a rectification ledger as soon as a warning letter is received, plan backwards from the deadline specified in the letter, retain all rectification evidence, and record the date of receipt of the letter as the start of the response window.
  • When assessing a suspension notice, first locate the grounds for cancellation it invokes (sections 41GK–41GN) and direct the evidence accordingly; the response should address the legal basis of the measure directly.
  • When considering an enforceable undertaking, commit only to remediation actions that are verifiable and deliverable by the company itself, with dates and owners attached to each.
  • Run an annual review of penalty unit amounts (they are adjusted by law) to support risk quantification, using the current unit value rather than a figure carried over from a previous assessment.

5. Verification checklist

  • □ The current stage of the enforcement process and the clauses invoked have been identified
  • □ A rectification ledger for the warning letter is in place with evidence retained
  • □ The grounds for cancellation cited in the suspension notice have been located
  • □ The civil and criminal penalty caps have been built into risk quantification at current penalty unit values
  • □ The content of any enforceable undertaking matches the company’s execution capability

Regulatory information verified as of 29 October 2026.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for the Australian market. Our team manages adverse event reporting and recall coordination with the TGA, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com

Disclaimer

Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.

About GRZAN

GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.

GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.

Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.

What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.

Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.

Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.

Take your devices global with GRZAN

We work with manufacturers worldwide to open new markets with a clear regulatory pathway.

Contact us
WhatsApp
QR Code
WhatsApp QR Code
Scan to chat on WhatsApp
Phone
Call
Office Mon-Fri 9:00-18:00
0755-88659477
Mobile 24/7 Service
+86 15816864648
Email
Mail